Equity Overview
Price & Market Data
Price: $4.39
Daily Change: -$0.10 / 2.28%
Daily Range: $4.38 - $4.57
Market Cap: $41,371,725
Daily Volume: 84,123
Performance Metrics
1 Week: 6.01%
1 Month: 5.25%
3 Months: -87.48%
6 Months: -83.11%
1 Year: -53.10%
YTD: -74.70%
Company Details
Employees: 10
Sector: Health technology
Industry: Biotechnology
Country:
Details
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.